Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) Chief Science Officer Rob Roscow tells Proactiveit had reached a new milestone in its artificial intelligence-powered drug discovery program. Roscow says it had completed a target-based model of serotonin receptor 5-HT2A, which will allow the company to quickly screen billions of compounds.
Mydecine said the model will help the company to understand the novel compounds that are most likely to increase binding ability, thus improving second and third generation psychedelic molecules for medical use.